EGFR and neoplasm: Overall, the daily combination of savolitinib 600 mg and gefitinib 250 mg showed acceptable safety profiles and promising anti-tumor activity in patients with advanced EGFRm and MET amplification NSCLC who had received previous EGFR-TKI treatment [66].